Abstract: The disclosure relates to compositions and methods for preventing, reducing, and/or treating scars. The compositions comprise at least one C-glycoside or derivative thereof, and the methods comprise treating skin and/or scar tissue with at least one C-glycoside or derivative thereof and at least one skin modification stimulus.

Abstract: The disclosure relates to compositions, methods, and kits for improving the appearance of the skin by applying acetyl trifluoromethylphenyl valylglycine, at least one retinoid, and optionally at least one additional skin peeling agent to the skin.

Abstract: The disclosure relates to compositions, methods, regimens, and kits for improving the appearance of the skin by applying acetyl trifluoromethylphenyl valylglycine and at least one peeling agent to the skin.

Abstract: The disclosure relates to novel compositions comprising 1) conditioned media, 2) combinations of secreted biomolecules/organic molecules, and/or 3) secreted extracellular vesicles/exosomes collected from differentiated epithelial cell culture, as well as methods of making and using such compositions.

Abstract: A method for improving skin comprising reducing the barrier function of skin, and applying a skin treatment composition to the skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: The present invention relates to a kit comprising a co-culture microdevice containing peripheral sensory neurons (PSN) and human epidermal keratinocytes (HEK) in a cell culture adapted for both cell types. It is also described a method for screening an active compound using the kit according to the present invention, as well as the use thereof for in vitro dmg tests and for producing a cosmetic product for various dermatological applications, such as atopic dermatitis, sensitive skin, photoaging, wound healing and epidermal thickness in aged skin.

Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.

Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.

Abstract: The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

Abstract: The invention relates to the use of a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of the LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of the NRAGE of SEQ ID NO: 2 for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible to treat skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Abstract: The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

Abstract: The invention relates to a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of LOX of sequence ID no. 1, and/or that modulates the expression and/or activity of NRAGE of sequence ID no. 2, for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins in order to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered.

Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The Invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Abstract: The invention relates to the stimulation of the activity of an isoform of lysyl oxidase, and more particularly of the LOX (lysyl oxidase) isoform.

Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (Iysyl oxidase-like) isoform.